Kim Langone PhD

Kim is Senior Director, Product Sciences at Genomic Health Inc. She has been with the company for over 16 years, during which time she was involved in the development and validation of Oncotype DX® gene expression tests for Breast Cancer (Breast Recurrence Score), Colon Cancer (Colon Recurrence Score) and Prostate Cancer (Genomic Prostate Score). More recently, she led the development of Oncotype SEQ® Liquid Select™, the first liquid and NGS-based product offering from Genomic Health. Kim was instrumental in developing the various platforms for these pioneering tests, leading both analytical and clinical validation studies and transitioning them from Development to the CLIA certified laboratory.

Kim therefore has a wealth of experience in what it takes to develop accurate, reliable and clinically actionable molecular diagnostic assays. Kim has been part of the Technical Application Group for The Blood Profiling Atlas in Cancer (Blood PAC) Consortium since 2016, as part of Biden’s Cancer Moonshot Initiative. Prior to joining Genomic Health, Kim studied the role of mitochondrial DNA dimers in cancer at Stanford University. Kim received her B.Sc. in Genetics and Ph.D. in Mitochondrial Genetics at the University of Newcastle Upon Tyne, England.